Skip to main content

Table 1 CFS/ME and healthy study control participant profile comparisons via representative pathology blood markers and cytokines

From: Activin B is a novel biomarker for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) diagnosis: a cross sectional study

Assay or measurement Study cohort Mean ± SEM p value
Age (years) Control 36.83 ± 2.03 0.78
CFS/ME 37.69 ± 1.78
Haemoglobin (g/L) Control 140.89 ± 2.48 0.64
CFS/ME 139.13 ± 2.12
Thyroid stimulating hormone (mIU/L) Control 1.38 ± 0.16 0.72
CFS/ME 1.45 ± 0.10
Vitamin D (nmol/L) Control 73.61 ± 7.73 0.71
CFS/ME 76.64 ± 3.99
Anion gap (mmol/L) Control 11.49 ± 0.55 0.14
CFS/ME 10.62 ± 0.30
GTT–blood glucose 30 min post load (mmol/L) Control 7.15 ± 0.52 0.45
CFS/ME 7.66 ± 0.27
GTT–blood insulin 30 min post load (mU/L) Control 50.88 ± 9.80 0.07
CFS/ME 81.33 ± 6.76
Interleukin-2 (pg/mL) Control 0.22 ± 0.12 0.09
CFS/ME 0.54 ± 0.11
Interleukin-4 (pg/mL) Control 0.26 ± 0.14 0.15
CFS/ME 0.55 ± 0.11
Interleukin-6 (pg/mL) Control 0.86 ± 0.25 0.20
CFS/ME 1.37 ± 0.20
Interleukin-10 (pg/mL) Control 1.06 ± 0.16 0.43
CFS/ME 1.18 ± 0.09
Interleukin-17A (pg/mL) Control Not detected N/A
CFS/ME Not detected
Interferon-γ (pg/mL) Control 0.57 ± 0.20 0.31
CFS/ME 0.37 ± 0.11
Tumour necrosis factor (pg/mL) Control Not detected N/A
CFS/ME Not detected
  1. Analyses comprised healthy controls (n = 17) and the CFS/ME cohort (n = 45), except for cytokine and GTT studies that compared n = 8–10 controls with n = 38–44 CFS/ME. Statistical significance was calculated by unpaired Mann–Whitney test
  2. GTT glucose tolerance test